Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next-generation ophthalmic technology, today reported positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The results validate the company's core technology and represent a key clinical de-risking milestone.
Key highlights include that the Group 1 data met or exceeded expectations for safety, lens delivery, and vision performance. Patients with severe vision loss, some with uncorrected preoperative acuities as poor as 20/250—consistent with legal blindness—experienced meaningful improvements in everyday vision. Dr. Rafael Vázquez, principal investigator of the trial, noted that patients who were classified as legally blind can now read, enjoy everyday activities, and drive, describing the change as life-changing.
"These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes," said Dean Burns, President and CEO of Ocumetics. "Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100% confident in our accommodating intraocular lens technology."
The results from Group 1 can be summarized as a safety profile that met expectations, visual acuity outcomes that met and exceeded expectations, and a lens delivery system that met expectations. This success has cleared the path to the next clinical phase, with planning for Group 2 surgeries already underway. The company has implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives based on insights from Group 1.
"All patient outcomes have met safety expectations," said Dr. Vázquez. "The profile of the patients I selected had poor vision, and as a result of the implantations, they have experienced truly a life changing event."
Ocumetics continues to apply its rapid "win-learn" R&D approach, incorporating surgeon feedback in real time. Manufacturing and testing of optimized lens designs are currently underway, with Group 2 surgeries expected to be scheduled following completion of final lens testing and validation.
For more information, Ocumetics will host a webinar on February 4, 2026, at 4:00 PM ET. Details can be found at www.ocumetics.com/webinar.
About Ocumetics: Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is in the first-in-human early feasibility study phase of a technology designed to allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. For further information, contact Dave Burwell, Director, Investor Relations, at www.ocumetics.com.
